{"result": "(\"entity\"<|>NATIONAL KIDNEY FOUNDATION<|>ORGANIZATION<|>The National Kidney Foundation is an organization that provides guidelines and resources for kidney health, including chronic kidney disease management.)\n##\n(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>The American Diabetes Association is an organization that sets standards for medical care in diabetes, focusing on complications and treatment strategies.)\n##\n(\"entity\"<|>DIABETIC NEPHROPATHY<|>EVENT<|>Diabetic nephropathy is a kidney disease that results from diabetes, characterized by the presence of albuminuria and reduced glomerular filtration rate.)\n##\n(\"entity\"<|>RETINOPATHY<|>EVENT<|>Retinopathy is a diabetes-related eye condition that can lead to vision loss, often requiring treatment such as laser therapy or medication.)\n##\n(\"entity\"<|>ALBUMINURIA<|>EVENT<|>Albuminuria is the presence of albumin in urine, indicating kidney damage, particularly in patients with diabetes.)\n##\n(\"entity\"<|>GLYCEMIC CONTROL<|>EVENT<|>Glycemic control refers to the management of blood glucose levels in individuals with diabetes to prevent complications such as diabetic nephropathy and retinopathy.)\n##\n(\"relationship\"<|>NATIONAL KIDNEY FOUNDATION<|>AMERICAN DIABETES ASSOCIATION<|>Both organizations provide guidelines and recommendations for managing diabetes-related complications, including kidney disease and retinopathy.<|>7)\n##\n(\"relationship\"<|>DIABETIC NEPHROPATHY<|>ALBUMINURIA<|>Albuminuria is a key indicator of diabetic nephropathy, as its presence signifies kidney damage in diabetic patients.<|>8)\n##\n(\"relationship\"<|>DIABETIC NEPHROPATHY<|>GLYCEMIC CONTROL<|>Optimizing glycemic control is essential in preventing and managing diabetic nephropathy.<|>9)\n##\n(\"relationship\"<|>RETINOPATHY<|>GLYCEMIC CONTROL<|>Maintaining strict glycemic control is crucial to reduce the risk and progression of retinopathy in diabetic patients.<|>9)\n##\n(\"relationship\"<|>RETINOPATHY<|>AMERICAN DIABETES ASSOCIATION<|>The American Diabetes Association provides standards of care that include management strategies for retinopathy.<|>6)\n##\n(\"relationship\"<|>ALBUMINURIA<|>RETINOPATHY<|>Both albuminuria and retinopathy are complications associated with diabetes, indicating systemic effects of the disease.<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 30-300 mg/g |\n| G3a | 45-59 ml/min/1,73 m² | A3 | >300 mg/g |\n| G3b | 30-44 ml/min/1,73 m² | | |\n| G4 | 15-29 ml/min/1,73 m² | | |\n| G5 | <15 ml/min/1,73 m² | | |\n\nAdaptado de: National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.\n---\nLa aparición de albuminuria sí parece depender en gran medida del inadecuado control glucémico. Sin embargo, una vez que existe albuminuria establecida, el factor dominante es la presión arterial, por el aumento de la presión intraglomerular, que es unos de los principales factores de progresión de la nefropatía diabética. Los dos aspectos fundamentales del tratamiento son la optimización del control glucémico y el tratamiento agresivo de la hipertensión arterial. Estas medidas son útiles tanto en la prevención de la afectación renal como en la prevención de su progresión.\n\nReferencias:\n- American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S124-38.\n- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.\n\n## 41 En pacientes con enfermedad renal diabética no dependiente de diálisis se recomienda:\n\nA. Una ingesta proteica de 0,5 g/kg/día.\nB. Una ingesta proteica de 0,8 g/kg/día.\nC. Una ingesta proteica de 1 g/kg/día.\nD. Ninguna de las anteriores es cierta.\n\n### COMENTARIO\n\nNo hay pruebas de que el ajuste del nivel diario de ingesta de proteínas (por lo general, 1,5 g/kg de peso corporal/día o 15-20% de calorías totales) mejore la salud de las personas sin enfermedad renal diabética, y la investigación no es concluyente con respecto a la cantidad ideal de proteína dietética para optimizar el control glucémico o el riesgo de enfermedad cardiovascular.\n\nLas personas con enfermedad renal diabética, con albuminuria y/o reducción de la tasa de filtración glomerular estimada, deben mantener las proteínas de la dieta en la cantidad diaria recomendada de 0,8 g/kg de peso corporal/día.\n\nReferencias:\n- American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S124-38.\n\n## 42 En un paciente con retinopatía no proliferativa moderada y sin edema macular, ¿qué tratamiento aconsejaría?\n\nA. Panfotocoagulación con láser.\nB. Estricto control glucémico y de presión arterial.\nC. Administración intravítrea de VEGF (anti-vascular endothelial growth factor).\nD. Todas son ciertas.\n\n### COMENTARIO\n\nSe debe optimizar el control glucémico para reducir el riesgo o disminuir la progresión de la retinopatía diabética. Además, se debe optimizar el control de la presión arterial y el control de los lípidos séricos para reducir el riesgo o disminuir la progresión de la retinopatía diabética.\n\nEl tratamiento estándar tradicional, la terapia de fotocoagulación con láser panretinal, está indicado para reducir el riesgo de pérdida de la visión en pacientes con retinopatía diabética proliferativa de alto riesgo y, en algunos casos, retinopatía diabética no proliferativa grave.\n\nLas inyecciones intravítreas del factor de crecimiento endotelial antivascular ranibizumab no son inferiores a la fotocoagulación con láser panretinal tradicional y también están indicadas para reducir el riesgo de pérdida de la visión en pacientes con retinopatía diabética proliferativa.\n\nLas inyecciones intravítreas de factor de crecimiento endotelial antivascular están indicadas para el edema macular diabético involucrado en el centro, que ocurre debajo del centro foveal y puede amenazar la visión con lectura.\n\nReferencias:\n- American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S124-38.\n\n## 43 Con respecto de la retinopatía diabética (RD), es falso lo siguiente:\n\nA. Es RD no proliferativa leve si solo hay microaneurismas.\nB. Es RD no proliferativa grave si tiene alteraciones venosas en más de dos cuadrantes.\nC. Es RD no proliferativa moderada si tiene malform\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}